Today, fool.com health-care analysts David Williamson and Brenton Flynn look at the biggest news across their sector.
One big headline is Geron's performance in August, when the company had weak results for one of its lead cancer drugs. While David doesn't think it spells doom for the company, it removes a big safety net for the company that investors could have previously counted on as a fall-back.
When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
